Related Experiment Video
Updated: May 17, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Aberrant genes promoter methylation in neural crest-derived tumors
Annamaria la Torre1, Lucia Anna Muscarella, Paola Parrella
1Laboratory of Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy.
Abstract:
Disturbances in the epigenetic landscape by aberrant methylation of CpG islands can lead to inactivation of cancer-related genes in solid tumors. We analyzed the promoter methylation status of 6 genes previously reported as cancer-specific methylated (MCAM, SSBP2, NISCH, B4GALT1, KIF1A and RASSF1A) in 38 neural crest-derived tumors by quantitative methylation-specific real-time PCR (QMSP). The results demonstrated that the determination of the methylation status of RASSF1A is able to distinguish between normal and tumor samples in cutaneous melanomas, lung carcinoids and small bowel carcinoids. MCAM methylation levels were significantly higher in lung carcinoids tumors (p=0.001), suggesting that this alteration may represent a molecular biomarker in this tumor type.
Insights
Aberrant DNA methylation of cancer genes is common in solid tumors. RASSF1A methylation distinguishes tumors from normal tissue, while MCAM methylation is elevated in lung carcinoids, indicating potential biomarkers.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Aberrant methylation of CpG islands disrupts the epigenetic landscape, leading to the inactivation of cancer-related genes in solid tumors.
- Understanding these epigenetic alterations is crucial for identifying novel cancer biomarkers and therapeutic targets.
Purpose of the Study:
- To analyze the promoter methylation status of six cancer-specific methylated genes in neural crest-derived tumors.
- To evaluate the potential of these genes as biomarkers for distinguishing between normal and tumor tissues, particularly in specific cancer types.
Main Methods:
- Quantitative methylation-specific real-time PCR (QMSP) was employed to assess the promoter methylation status of six genes (MCAM, SSBP2, NISCH, B4GALT1, KIF1A, and RASSF1A).
- The analysis was performed on 38 neural crest-derived tumors.
Main Results:
- RASSF1A promoter methylation successfully distinguished between normal and tumor samples in cutaneous melanomas, lung carcinoids, and small bowel carcinoids.
- Significantly higher MCAM methylation levels were observed in lung carcinoid tumors (p=0.001).
Conclusions:
- RASSF1A methylation serves as a reliable biomarker for differentiating tumor from normal tissue across several cancer types.
- MCAM methylation may represent a valuable molecular biomarker specifically for lung carcinoid tumors, warranting further investigation.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Induced Pluripotent Stem Cells
Somatic cells are...
Abnormal Proliferation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

